About 20% of patients — as many as 1 in 5 — may not respond well to medications like Mounjaro and Wegovy, according to ...
The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.
The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and ...
In a randomized controlled trial of people with type 2 diabetes, albuminuria, and estimated glomerular filtration rate (eGFR) between 25 and 75 mL/min/1.73 m2, subcutaneous semaglutide reduced the ...
About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...
GLP-1RA dispensing has increased from 2022 and 2023, whereas metabolic bariatric surgery has decreased among individuals with obesity.
Compared with standard AUD medications, the use of semaglutide and liraglutide was linked to a lower risk for alcohol use ...
The impact of GLP-1 RAs on alcohol use is explored, showing potential benefits in reducing intake and cravings, but with ...
The following is a summary of “Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis,” published in the November ...
A recent study found that glucagon-like peptide-1 receptor (GLP-1) agonists like semaglutide and liraglutide are effective in ...
Metformin and GLP-1 receptor agonists significantly reduce asthma attacks in patients with type 2 diabetes, offering ...